Impaired dopamine release in Parkinson’s disease
Open accessThe DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index.
Abstract
Parkinson’s disease is the second most common neurodegenerative disease and yet the early pathophysiological events of the condition and sequences of dysfunction remain unclear. The loss of dopaminergic neurons and reduced levels of striatal dopamine are descriptions used interchangeably as underlying the motor deficits in Parkinson’s disease. However, decades of research suggest that dopamine release deficits in Parkinson’s disease do not occur only after cell death, but that there is dysfunction or dysregulation of axonal dopamine release before cell loss. Here we review the evidence for dopamine release deficits prior to neurodegeneration in Parkinson’s disease, drawn from a large and emerging range of Parkinson’s disease models, and the mechanisms by which these release deficits occur. The evidence indicates that impaired dopamine release can result from disruption to a diverse range of Parkinson’s disease-associated genetic and molecular disturbances, and can be considered as a potential pathophysiological hallmark of Parkinson’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This lack of dopamine is understood to be the primary cause of many of the movement disorders [127,128].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469 · cited 1×
“1).(2,3) SNpc neurons project to the dorsal striatum form-”
BackgroundMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 2×
“Loss-of-function mutations in parkin are the most common cause of autosomal recessive Parkinson’s.95 Parkin, encoded by the PRKN gene (previously known as PARK2), is an E3 ubiquitin ligase that regulates proteasome-dependent protein degradation and plays a critical role in mitochondrial quality control.”
BackgroundAGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529 · cited 1×
“1).(2,3) SNpc neurons project to the dorsal striatum form-”
BackgroundHereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481 · cited 1×
“PINK1 is a mitochondrial protein kinase in which loss-of-function mutations are the second most frequent known cause of autosomal recessive Parkinson’s disease.(96) This protein regulates the activity of parkin, affects mitochondrial stability and modulates mito-”
BackgroundMutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563 · cited 1×
“Models employing SNpc or intrastriatal PFF injections that take advantage of the connectivity to the SNpc have the advantages that they have been shown to aggregate endogenous α-synuclein, induce progressive DA system neurodegeneration specific to SNpc while sparing the ventral tegmental area and recapitulate Parkinso…”
BackgroundThe Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro
Burré, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M. R., & Südhof, T. C. (2010) · Science · doi:10.1126/science.1195227 · Cited by 1,812
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765 · cited 2×
“TH, the rate-limiting enzyme in DA synthesis, has been shown to have decreased protein levels or decreased activity in models of Parkinson’s disease carrying mutations in LRRK2, SNCA, DJ-1 and PINK1.”
BackgroundMice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
Cited by
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
Neuropathogenesis-on-chips for neurodegenerative diseases
Amartumur, S., Nguyen, H. M., Huynh, T., Kim, T. S., Woo, R., Oh, E., Kim, K. K., Lee, L. P., & Heo, C. (2024) · Nature Communications · doi:10.1038/s41467-024-46554-8 · Cited by 141
“Corresponding to dopamine depletion, severalpathologicalprocesses that regulate dopamine synthesis occur in the brain 254 .”
BackgroundThe gut microbiota–brain axis in neurological disorders
You, M., Chen, N., Yang, Y., Cheng, L., He, H., Cai, Y., Liu, Y., Liu, H., & Hong, G. (2024) · MedComm · doi:10.1002/mco2.656 · Cited by 133
“155,194 It has been reported that GI disorders and gut dysbiosis occur before the onset of motor symptoms in PD. 195 Aggregation of α - Synuclein ( α Syn) is a characteristic protein in PD, which usually leads to motor dysfunction.”
BackgroundInfluentialLevodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression
Riederer, P. F., Strobel, S., Nagatsu, T., Watanabe, H., Chen, X. M., Löschmann, P. A., Sian‐Hülsmann, J., Jost, W. H., Müller, T., Dijkstra, J. M., et al. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02893-4 · Cited by 126
“This is probably due to the inability of the compensation mechanisms to overcome the progressive cellular dysfunction (Cramb et al. 2023).”
Liu, Y., Zhang, Y., Wang, C., Zeng, X., Lei, J., Hou, J., Huo, D., & Hou, C. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c06213 · Cited by 69
Speranza, L., Miniaci, M. C., & Volpicelli, F. (2025) · Biomedicines · doi:10.3390/biomedicines13020492 · Cited by 61
“While the classic motor symptoms of PD—such as tremors, stiffness, and slow movement—are primarily attributed to a lack of dopamine in brain regions like the striatum, recent research has revealed that the underlying molecular mechanisms are much more complex than initially thought [1,4,6].”
Zhang, C., Shao, W., Yuan, H., Xiao, R., Zhang, Y.-R., Wei, C., Ni, X., He, N., Chen, G., Gui, S., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c04674 · Cited by 60
Gan, Q., Peng, M., Wei, H., Chen, L., Chen, X.-Y., Li, Z.-H., An, G., & Ma, Y. (2024) · Food & Function · doi:10.1039/d3fo05169b · Cited by 59
Humińska‐Lisowska, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111602 · Cited by 57
Wang, X., Xu, M., Yang, H., Jiang, W., Jiang, J., Zou, D., Zhu, Z., Tao, C., Ni, S., Zhou, Z., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c12429 · Cited by 50
Watanabe, H., Dijkstra, J. M., & Nagatsu, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042009 · Cited by 48
“Interestingly, various mutations are believed to decrease DA release before the cells degenerate [178].”
Slézia, A., Hegedüs, P., Rusina, E., Lengyel, K., Solari, N., Kaszás, A., Balázsfi, D., Botzanowski, B., Acerbo, E., Missey, F., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46576-0 · Cited by 51
“Second, functional deficits without cell death have already been demonstrated in some studies 87 .”
Lei, T., Li, C., Liu, Y., Cui, Z., Deng, S., Cao, J., Yang, H., & Chen, P. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02587-1 · Cited by 49
“PD patients present with significant dopaminergic neuronal loss and decreased dopamine secretion, so almost treat-ment strategies revolve around dopamine callback [2].”
BackgroundRegulation of iron metabolism in ferroptosis: From mechanism research to clinical translation
Zhang, X., Yang, X., Wang, Q., Bai, X., Meng, D., Wu, J., Sun, K., Zhang, L., Qiang, R., Liu, W., et al. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101304 · Cited by 50
“Additionally, there is evidence that certain metabolites of dopamine can interact with iron to produce neurotoxic substances, potentially hindering the recovery of motor function in PD patients [23].”
Mitophagy’s impacts on cancer and neurodegenerative diseases: implications for future therapies
Huang, J. B., Pham, V. T., Fu, S., Huang, G., Liu, Y., & Zheng, L. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01727-w · Cited by 45
PANoptosis: Cross-Talk Among Apoptosis, Necroptosis, and Pyroptosis in Neurological Disorders
Li, P., Gao, Y., Tao, Z., Mu, Z., Du, S., & Zhao, X. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s526158 · Cited by 43
“42 It is characterized by movement problems such as tremors, stiffness, slow movement, and balance difficulties.”
Meca, A.-D., Boboc, I. K. Ş., Mititelu-Tarțău, L., & Bogdán, M. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46060354 · Cited by 33
Wekalao, J., & Mandela, N. (2024) · Plasmonics · doi:10.1007/s11468-024-02570-4 · Cited by 29
Yadav, P. K., Benner, D., Varshney, R., Kansara, K., Shah, K., Dahle, L., Kumar, A., Rawal, R., Gupta, S. K., & Bhatia, D. D. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c00249 · Cited by 31
LRRK2-mediated mitochondrial dysfunction in Parkinson’s disease
Buck, S. A., & Sanders, L. H. (2025) · Biochemical Journal · doi:10.1042/bcj20253062 · Cited by 29
An, J., Shin, M., Beak, G., Yoon, J., Kim, S., Cho, H., & Choi, J. (2024) · ACS Sensors · doi:10.1021/acssensors.4c00476 · Cited by 25
Piezoelectric-enhanced ultrasensitive ZnO/Ag microcavity SERS substrate for dopamine detection
Deng, W., Yuan, L., Wan, P., Sun, J., Kan, C., Shi, D., Xu, C., & Lu, J. (2024) · Nano Energy · doi:10.1016/j.nanoen.2024.110449 · Cited by 24
Cheng, G., Liu, Z., Yan, Z., Wu, J., Li, Z., Gao, S., Zheng, C., Guo, S., Pan, Y., Chen, X., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.066 · Cited by 23
Babu, H. W. S., Muthukumar, S., Kaur, H., Iyer, M., & Vellingiri, B. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122610 · Cited by 25
Research Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer’s Disease
Yang, Y., & Qiu, L. (2024) · Brain Sciences · doi:10.3390/brainsci14060590 · Cited by 23
Du, Y., Liu, Y., Lu, W., Zhang, X., Wang, A., & Kong, J. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c13815 · Cited by 21
Ahmed, H. S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04156-x · Cited by 22
Gao, Y., Li, S., Zhang, S., Zhang, Y., Zhang, J., Zhao, Y., Cui, C., Gao, X., Chen, L., & Yang, G. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04258-x · Cited by 20
Chen, S., Jiang, D., Li, M., Xuan, X., & Li, H. (2025) · ACS Sensors · doi:10.1021/acssensors.4c02461 · Cited by 22
Zhang, F., Liu, M., Tuo, J., Zhang, L., Zhang, J., Yu, C., & Xu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1253273 · Cited by 19
Chen, L., Xu, H., Gong, T., Jin, J., Lin, L., Zhou, Y., Huang, J., & Chen, Z. (2024) · Magnetic Resonance in Medicine · doi:10.1002/mrm.30233 · Cited by 20
Yang, Z., Guo, H., Sun, L., Yu, Z., & Yang, W. (2025) · Talanta · doi:10.1016/j.talanta.2025.128614 · Cited by 18
Mirror-Image L-DNA Aptamers Enable Stable In Vivo Dopamine Sensing
Liu, Y., Jin, Y., Zhu, F., Li, X., Ma, C., Sun, Z., Yao, Y., Song, K., Mao, L., & Jiang, Y. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c22265 · Cited by 17
Emerging biophysical techniques for probing synaptic transmission in neurodegenerative disorders
Kale, M. B., Wankhede, N. L., Bishoyi, A. K., Ballal, S., Kalia, R., Arya, R., Kumar, S., Khalid, M., Gulati, M., Umare, M. D., et al. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.11.055 · Cited by 18
G-protein coupled receptors in neuroinflammation, neuropharmacology, and therapeutics
Singh, A. P., Shadangi, S., & Rana, S. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117301 · Cited by 18
Credico, A. D., Weiss, A., Corsini, M., Gaggi, G., Ghinassi, B., Wilbertz, J. H., & Baldassarre, A. D. (2023) · Scientific Reports · doi:10.1038/s41598-023-49364-y · Cited by 17
“It is known that cellular TH levels decrease during PD, affecting dopamine synthesis [40].”
BackgroundCai, T., Zhang, W., Charlton, F., Sun, Y., Chen, Y., Fu, Y., Zhang, Q., & Liu, S. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117444 · Cited by 16
Kasanga, E. A., Han, Y., Shifflet, M. K., Navarrete, W., McManus, R., Parry, C., Barahona, A., Nejtek, V. A., Manfredsson, F. P., Kordower, J. H., et al. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114509 · Cited by 15
Wang, X., Jiang, W., Yang, H., Ye, Y., Zhou, Z., Sun, L., Nie, Y., Tao, T. H., & Wei, X. (2024) · Micromachines · doi:10.3390/mi15040447 · Cited by 16
Ou, Z., You, Y., Yi, H., Liu, X., Tong, Y., Liu, D., & Wang, J. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s468942 · Cited by 15
Loreto, A., Cramb, K. M. L., McDermott, L., Antoniou, C., Cirilli, I., Caiazza, M. C., Merlini, E., Arthur‐Farraj, P., du Preez, W. D., Mock, E. D., et al. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106986 · Cited by 15
“They also confirm that SARM1 activation is detectable before morphological damage is present and that mitochondrial dysfunction precedes axon degeneration in hiPSC-DANs after SARM1 activation, and this coincides with detectable metabolic changes.”
Self-citationChen, Y., Qi, Y., Li, T., Lin, A., Ni, Y., Pu, R., & Sun, B. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1393841 · Cited by 15
“Techniques like functional MRI (fMRI) ( Shi et al., 2022, 2023) and positron emission tomography (PET) can detect patterns of activity and metabolic changes in the brain, providing real-time information about the functioning of different brain regions (Rischka et al., 2021; Malén et al., 2022).”
Ma, W., Zhao, G., Liu, R., Li, K., Wu, W., Liu, J., He, X., Hou, L., Yu, P., & Mao, L. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202502163 · Cited by 14
Effects and mechanisms of bisphenols exposure on neurodegenerative diseases risk: A systemic review
Xu, Y., Nie, J., Lu, C., Hu, C., Chen, Y., Ma, Y., Huang, Y., & Lu, L. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.170670 · Cited by 15
Kearney, P. J., Zhang, Y., Liang, M., Tan, Y., Kahuno, E. W., Conklin, T. L., Fagan, R. R., Pavchinskiy, R. G., Shaffer, S. A., Yue, Z., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00648-8 · Cited by 14
“Interestingly,DAreleaseisadverselyaffectedpriortoDANdegenerationin severalexperimentalPDmodels 45,47 , raising the possibility that the altered DA release we observed following ST Rit2 KD may, likewise, forbode the imminent DAN degeneration.”
BackgroundThe effects of Nardosinone on levodopa intervention in the treatment of Parkinson's disease
Liu, M., Xue, J., Cao, Y., Hao, Z., Wang, Y., Li, J., Jiang, T., & Shi, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116448 · Cited by 13
An activated fluorescent probe to monitor NO fluctuation in Parkinson's disease
Liu, T., Han, X., Sun, X., Zhang, W., Gao, K., Min, R., Tian, Y., & Yin, C. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110170 · Cited by 12
Investigation of Electrocatalytic Applications of Various Advanced Nanostructured Alloys—An Overview
Shashanka, R., Chalageri, G. R., Mahale, R. S., Altaş, E., Chapke, Y., & Adimule, V. M. (2025) · Catalysts · doi:10.3390/catal15030259 · Cited by 14
“…and mental health, increase anxiety and depression, and cause attention deficit hyperactivity disorder (ADHD), Parkinson’s disease, compulsive and depression, and cause attention deficit hyperactivity disorder (ADHD), Parkinson’s disease, compulsive behavior, sleeping disorders, etc. [65–68].”
Eisenstein, T., Groenewald, K., van Hillegondsberg, L., Alhajraf, F., Zerenner, T., Lawton, M., Ben‐Shlomo, Y., Griffanti, L., Hu, M. T., & Klein, J. C. (2025) · Brain · doi:10.1093/brain/awaf168 · Cited by 15
Alum, E. U., Akwari, A. A., Okoroh, P. N., Aniokete, U. C., Abba, J. N., & Uti, D. E. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10752-4 · Cited by 12
Therapeutic potential of mesenchymal stem cells in neurodegenerative diseases
Cui, C.-X., Shao, X.-N., Li, Y., Qiao, L., Lin, J., & Guan, L. (2025) · World Journal of Stem Cells · doi:10.4252/wjsc.v17.i8.107717 · Cited by 13
Neurotransmitters in Neural Circuits and Neurological Diseases
Gholami, A., & Mortezaee, K. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00426 · Cited by 12
Cheng, T., Afshan, N., Jiao, J., & Jiao, J. (2024) · Biosensors and Bioelectronics X · doi:10.1016/j.biosx.2024.100528 · Cited by 16
Animal Models of Parkinson's Disease
Dawson, V. L., & Dawson, T. M. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041644 · Cited by 12
Yang, R., He, C., Zhang, P., Li, Y., Rong, S., Chen, X., Qi, Q., Gao, Z., Chi, J., Wang, L., et al. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107071 · Cited by 12
“Dopaminergic degeneration in the substantia nigra and striatum is a pathological hallmark of PD [17].”
Li, Q.-M., Xu, H., Zha, X., Zhang, F., & Luo, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143986 · Cited by 11
Yang, Z., Sun, L., Guo, H., & Yang, W. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.115416 · Cited by 11
Saenz, J., Khezerlou, E., Aggarwal, M., Shaikh, A., Ganti, N., Herborg, F., & Pan, P. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00769-0 · Cited by 11
“Parkinson ’ s disease (PD) is often preceded by altered dopamine (DA) signaling and loss of functional maintenance of DAergic axons 9,63,70 – 79 .”
BackgroundShao, X., Li, M., Shi, S., Wu, T., Zhang, Y., Guo, S., Lin, H., & Qi, X. (2025) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x25500314 · Cited by 11
Single-cell sequencing insights into the transcriptional landscape of Parkinson's disease
Su, Y., Zheng, H., Cui, X., Zhang, S., Zhang, S., Hu, Z., Hao, X., Li, M., Guo, G., Xia, Z., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102553 · Cited by 10
Parkinson’s Disease Dementia Patients: Expression of Glia Maturation Factor in the Brain
Thangavel, R., Kaur, H., Dubova, I., Selvakumar, G. P., Ahmed, M. E., Raikwar, S. P., Govindarajan, R., & Kempuraj, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021182 · Cited by 9
“Dopamine is the neurotransmitter in dopaminergic neurons, and disturbances in dopamine lead to dopaminergic neurodegeneration in PD [14,15].”
BackgroundThe role of interleukin (IL)-2 cytokine family in Parkinson's disease
Goleij, P., Amini, A., Tabari, M. A. K., Hadipour, M., Sanaye, P. M., Alsharif, K. F., Daglia, M., Larsen, D. S., & Khan, H. Z. (2025) · Cytokine · doi:10.1016/j.cyto.2025.156954 · Cited by 11
Lamichhane, S., Seo, J., Jeong, J. H., Lee, S., & Lee, S. (2024) · Archives of Pharmacal Research · doi:10.1007/s12272-024-01527-9 · Cited by 9
“Similarly, LRRK2 mutations, such as G2019S (in the kinase domain) and R1441C (in the guanosine triphosphatase domain), are associated with late-onset autosomal dominant PD. LRRK2 overexpression, particularly G2019S, in mouse models, results in mild or non-disrupted nigrostriatal dopamine (DA) neurons, with progressive…”
InfluentialChen, H., Xu, H., Zhang, W., Luo, Z.-Y., Zhang, Z., Shi, H.-H., Dong, Y.-C., Xie, Z., Ben, Y., & An, S. (2024) · Current Stem Cell Research & Therapy · doi:10.2174/011574888x301827240613063513 · Cited by 8
A toxic gain-of-function variant in MAPK8IP3 provides insights into JIP3 cellular roles
Zhang, W., Mittal, S., Thomas, R., Foroughishafiei, A., Bastos, R. N., Chung, W. K., Skourti-Stathaki, K., & Crooke, S. T. (2025) · JCI Insight · doi:10.1172/jci.insight.187199 · Cited by 8
Liu, Y., Zhang, J., Tang, L., Yang, J., Hao, L., Lou, F., & Su, J. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04174-1 · Cited by 9
“The substantia nigra is a key component of the basal ganglia, responsible for coordinating and regulating movement (Cramb et al. 2023; Zhai et al. 2023).”
Cutter, L. R., Ren, A. R., & Banerjee, I. A. (2025) · Molecules · doi:10.3390/molecules30214302 · Cited by 8
“Preserving the activity of dopaminergic cells and regulation of neurotransmitters are therefore key factors to be considered when developing therapeutics for Parkinson’s disease (PD) [122].”
Mihajlović, K., Malod‐Dognin, N., Ameli, C., Skupin, A., & Pržulj, N. (2024) · NAR Molecular Medicine · doi:10.1093/narmme/ugae012 · Cited by 9
“…of these mechanisms caused by dysfunctional genes might represent early signs of disrupted ability to release dopamine from mDA neurons [20], leading to the appearance of motor symptoms characteristic of PD. DAPs are additionally associated with the Metabolism of lipids , specifically…”
BackgroundCarvajal-Oliveros, A., Román-Martínez, C., Reynaud, E., & Martínez‐Martínez, E. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1485414 · Cited by 8
Geva, M., Goldberg, Y. P., Schuring, H., Tan, A. M., Long, J. D., & Hayden, M. R. (2025) · Movement Disorders · doi:10.1002/mds.30164 · Cited by 8
“30,45 However, it is not clear whether the worsening of clinical measures associated with ADM use is permanent.”
Chen, C., He, Q., Tombesi, G., Napier, E., Jaconelli, M., Moreno-Ramos, O. A., Serio, H., Naaldijk, Y., Promes, V., Schneeweis, A. K., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75194-3 · Cited by 5
“…patients, it is estimated that dopamine terminal loss can be ~60%, whereas dopamine cell bodies loss is approximately 30% 88,89 Furthermore, imaging studies in non-manifesting LRRK2 mutation carriers 90,91 and in prodromal PD cohorts reveal presynaptic de fi cits prior to motor symptom onset 21,92 .”
Seiler, J. L., Zhuang, X., Nelson, A., & Lerner, T. N. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114693 · Cited by 7
Gao, Y., Liu, Y., Zhang, Y., Li, Y., & Zhang, L. (2024) · Microchemical Journal · doi:10.1016/j.microc.2024.111147 · Cited by 7
Liu, L., Zhao, Y., Yang, W., Han, L., Mo, X., Sheng, J., Tian, Y., & Gao, X. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041676 · Cited by 7
“In rotenone-induced PD mice, studies have shown a significant reduction in the number of TH-positive cells and loss of DA nerve cells [33].”
New insights into axonal regulators of dopamine transmission in health and disease
Todd, K. L., Cramb, K. M. L., Brimblecombe, K. R., & Cragg, S. J. (2025) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2025.103093 · Cited by 7
Self-citationThe Role of Stem Cell Therapies in the Treatment of Neurodegenerative Diseases
Jayaprakash, B., Savira, M., Mahmood, A. A. R., & Prasanna, M. (2024) · Current Stem Cell Research & Therapy · doi:10.2174/011574888x313112240510160102 · Cited by 7
Weishaupt, A.-K., Ruecker, L., Meiners, T., Schwerdtle, T., Ávila, D. S., Aschner, M., & Bornhorst, J. (2024) · Toxicological Sciences · doi:10.1093/toxsci/kfae092 · Cited by 7
Metabolism and metabolomics in senescence, aging, and age-related diseases: a multiscale perspective
Wang, Z., Zhu, H., & Xiong, W. (2025) · Frontiers of Medicine · doi:10.1007/s11684-024-1116-0 · Cited by 7
Sanchiz-Calvo, M., Coccia, E., Cawthorne, C., Parfitt, G. M., Torre-Muruzabal, T., Tsafaras, G., Laere, K. V., Cabezudo, D., Cascalho, A. C. C., den Haute, C. V., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02908-0 · Cited by 6
Seif, P. (2025) · PubMed Central · doi:10.36131/cnfioritieditore20250306 · Cited by 9
“While Parkinson’s disease involves nigrostriatal dopamine depletion (Cramb et al., 2023), catatonia extends beyond basal ganglia dysfunction to involve mesocortical and limbic circuits (Walther et al., 2019).”
Kumari, A., Behera, P. K., Bansal, D., & De, M. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c18321 · Cited by 6
Fu, X., Ni, S., & Al‐qaness, M. A. A. (2025) · Engineering Applications of Artificial Intelligence · doi:10.1016/j.engappai.2025.113506 · Cited by 6
Roles of synaptic cell adhesion molecules in the neuromodulatory systems
Li, J., Kawasawa, Y. I., Uchigashima, M., & Futai, K. (2026) · Molecules and Cells · doi:10.1016/j.mocell.2026.100340 · Cited by 6
“…the etiology of these disorders, including autism spectrum disorder (ASD), schizophrenia (SCZ), attention-deficit/hyperactivity disorder (ADHD), Parkinson’s (PD), and Alzheimer’s disease (Cramb et al., 2023; Jackson et al., 2025; Klein et al., 2019; Kosillo & Bateup, 2021; Pourhamzeh et al., 2022).”
Nanocarriers-Assisted Nose-to-Brain Delivery of Levodopa: Current Progress and Prospects
Dangova, M., Ivanova, N. A., & Andonova, V. (2024) · Applied Sciences · doi:10.3390/app15010331 · Cited by 6
Metal-organic framework mimetic enzymes: Exploring new horizons in brain chemistry
Liu, C., Wang, Y., Bao, Y., & Lin, Y. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110652 · Cited by 8
Cometto, M. J., Naranjo-Viteri, A. J., Champarini, L. G., Hereñú, C. B., & Crespo, R. (2025) · Plants · doi:10.3390/plants14070999 · Cited by 8
“Because the axons of SN neurons arborize profusely within CPU [16], TH and DAT are reliable markers of terminal dopamine innervation in the brain structure [17].”
Synergistic effect of acoustic streaming and nanozymes on enhanced intracellular dopamine detection
Zhu, F., Hu, X., Wu, X., Xu, D., Li, Q., Chen, X., Pang, W., Duan, X., Wang, Y., & He, M. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117431 · Cited by 6
Lee, N., Lee, D., Lee, J. H., Lee, B. S., Kim, S., Kim, J. H., & Jeong, S. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101485 · Cited by 5
Thioredoxin-1 Downregulation in the SNpc Exacerbates the Cognitive Impairment Induced by MPTP
Zhang, X., Yan, F., He, X. J., Chen, Y., Gu, R., Dong, X., Wei, Y., Bai, L., & Bai, J. (2025) · Antioxidants and Redox Signaling · doi:10.1089/ars.2024.0630 · Cited by 6
“Introduction P arkinson ’ s disease (PD) is a progressive disorder marked by the degeneration of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNpc) (Cramb et al., 2023; Zhou, 2024).”
Alpinetin Targets Mitophagy Pathways to Mitigate Parkinson's Disease Progression
Shen, Z., Shan, X., Zhang, S., Huang, D. A., Hu, H., Liang, Y., Zhu, H. B., Zhang, L., & Chen, Y. (2025) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70676 · Cited by 5
“The structural organization of dopaminergic synapses is centered on presynaptic terminals, which house key mechanisms governing dopamine synthesis, storage, and release [74, 75].”
Aslan, F. Ş., Barut, B., Ozturk, S., Eyigürbüz, T., & Akyüz, E. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00809 · Cited by 9
“62 DA exerts its effects by binding to G protein-coupled receptors after being released into the synaptic cleft.”
Sperlich, C. L., Stockwell, B. R., & Farina, M. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70438 · Cited by 5
Xi, W., Kong, Z., Zhang, L., Zhang, Z., Huang, X., Liu, H., Deng, Z., Liu, J., Cui, X., Li, Z., et al. (2024) · Diamond and Related Materials · doi:10.1016/j.diamond.2024.111540 · Cited by 7
Sun, Y., & Zheng, M. J. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.113750 · Cited by 5
Birioukova, L. M., van Luijtelaar, G., & Midzyanovskaya, I. S. (2024) · Receptors · doi:10.3390/receptors3010004 · Cited by 5
“The impaired activity of DA and its receptors is a pathological factor for many neurological human brain diseases, the most frequently mentioned of which are Parkinson’s disease and schizophrenia [13–16].”
BackgroundNanozymes in Parkinson's disease: strategic approaches, clinical considerations, and challenges
Huang, W., Ye, X., Huang, Z. J., Li, M., Yu, B., Ye, L., He, S., & Chen, C. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00295h · Cited by 4
Redefining dopaminergic synapses beyond the classical paradigm
Fujise, K., Mishra, J., Karmali, N., & Rafiq, N. M. (2025) · Trends in Neurosciences · doi:10.1016/j.tins.2025.09.011 · Cited by 5
Rizvi, A., Chinnapaiyan, S., Nandhini, C., Lin, J.-H., Kamaraj, J. J. J. J., Wahyuono, R. A., & Huang, C. (2025) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2025.106533 · Cited by 4
Liu, T., Fan, H., Lin, R.-X., Liu, A.-D., Feng, J.-C., Zeng, Y., Chen, H., Zhong, H., Xia, J.-C., Lin, X., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157601 · Cited by 5
Rodríguez-Aller, R., Romero-Quineche, B., Morissette, M., Sheta, R., Paolo, T. D., Saghatelyan, A., & Oueslati, A. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01201-x · Cited by 4
“Moreover, several imaging studies in PD patients have also con fi rmed synaptic dysfunction during the prodromal phase, occurring several years before the onset of motor symptoms 20,21 .”
Metadata
- Authors
- Cramb, K. M. L., Beccano-Kelly, D., Cragg, S. J., & Wade-Martins, R.
- Affiliations
- University of Oxford (GB)
- Oxford Parkinson’s Disease Centre and Department of Physiology, Anatomy and Genetics, University of Oxford , Oxford, OX1 3QU , UK
- Corresponding author
- Cragg, Stephanie J
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-03-02
- Volume
- 146
- Issue
- 8
- Pages
- 3117-3132
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC10393405
- OpenAlex
- W4323036321
- Cited by
- 207
- References
- 157
- Citations by year
- 2026: 63 · 2025: 75 · 2024: 60 · 2023: 8
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Monument Trust Discovery Award from Parkinson’s UK (J-1403)
- MJFF (ASAP-020370)
- Natural Sciences and Engineering Research Council of Canada (PGSD3-517039-2018)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- Parkinson's disease, dopamine release, dopaminergic neurons, striatal dopamine, neurodegeneration, Parkinson's disease model, pathophysiology
- MeSH terms
- Dopamine, Humans, Parkinson Disease, Neurodegenerative Diseases, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.